Aptamer Sciences Inc
Aptamer Sciences Inc, a bio venture company, focuses on the Aptamer technology platform for the development of therapeutic and diagnostic platforms. The company's platforms include aptamer discovery, optimization, and the development of therapeutics and diagnostics for cancer and neurological disorders. It offers AlloMAp and Bi-Functional Aptame (BiFAp) platform programs for therapeutics, as well… Read more
Market Cap & Net Worth: Aptamer Sciences Inc (291650)
Aptamer Sciences Inc (KQ:291650) has a market capitalization of $29.68 Million (₩43.45 Billion) as of March 19, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #26388 globally and #1691 in its home market, demonstrating a 3.99% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Aptamer Sciences Inc's stock price ₩1484.00 by its total outstanding shares 29280252 (29.28 Million).
Aptamer Sciences Inc Market Cap History: 2020 to 2026
Aptamer Sciences Inc's market capitalization history from 2020 to 2026. Data shows change from $230.29 Million to $29.68 Million (-31.44% CAGR).
Index Memberships
Aptamer Sciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$167.85 Billion | 0.01% | #901 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$167.85 Billion | 0.01% | #901 of 1384 |
Weight: Aptamer Sciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Aptamer Sciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Aptamer Sciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.02x
Aptamer Sciences Inc's market cap is 0.02 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $230.29 Million | $228.51 Million | -$3.84 Billion | 1.01x | N/A |
| 2021 | $145.42 Million | $269.28 Million | -$3.83 Billion | 0.54x | N/A |
| 2022 | $74.63 Million | $358.25 Million | -$7.12 Billion | 0.21x | N/A |
| 2023 | $61.50 Million | $243.19 Million | -$13.60 Billion | 0.25x | N/A |
| 2024 | $21.88 Million | $1.08 Billion | -$8.70 Billion | 0.02x | N/A |
Competitor Companies of 291650 by Market Capitalization
Companies near Aptamer Sciences Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Aptamer Sciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Aptamer Sciences Inc Historical Marketcap From 2020 to 2026
Between 2020 and today, Aptamer Sciences Inc's market cap moved from $230.29 Million to $ 29.68 Million, with a yearly change of -31.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩29.68 Million | +95.78% |
| 2025 | ₩15.16 Million | -30.71% |
| 2024 | ₩21.88 Million | -64.42% |
| 2023 | ₩61.50 Million | -17.60% |
| 2022 | ₩74.63 Million | -48.68% |
| 2021 | ₩145.42 Million | -36.85% |
| 2020 | ₩230.29 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Aptamer Sciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $29.68 Million USD |
| MoneyControl | $29.68 Million USD |
| MarketWatch | $29.68 Million USD |
| marketcap.company | $29.68 Million USD |
| Reuters | $29.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.